Literature DB >> 10729656

A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia.

S M Bhavnani1, J A Drake, A Forrest, J A Deinhart, R N Jones, D J Biedenbach, C H Ballow.   

Abstract

National Nosocomial Resistance Surveillance Group participants from 22 hospitals across the United States reviewed medical records for hospitalized patients with vancomycin-resistant enterococcal (VRE) or vancomycin-susceptible enterococcal (VSE) bacteremia to identify risk factors associated with the acquisition of VRE bacteremia, describe genetic traits of VRE strains, and identify factors predictive of clinical outcome. VRE cases were matched to VSE controls within each institution. Multiple logistic regression (LR) and classification and regression tree (CART) analysis were used to probe for factors associated with VRE bacteremia and clinical outcome. A total of 150 matched-pairs of VRE cases and VSE controls were collected from 1995 to 1997. Using LR, the following were found to be highly associated with VRE bacteremia: history of AIDS, positive HIV status, or drug abuse (OR 9.58); prior exposure with parenteral vancomycin (OR 8.37); and liver transplant history (OR 6. 75). CART analysis revealed that isolation of Enterococcus faecium, prior vancomycin exposure, and serum creatinine values > or = 1.1 mg/dl were predictors of VRE bacteremia. Greater proportions of clinical failure (60% versus 40%, P < 0.001) and all-cause mortality (52% versus 27%, P < 0.001) were seen in patients with VRE versus VSE bacteremia. Results from both LR and CART indicated that patients with persisting enterococcal bacteremia, intubation at baseline, higher APACHE II scores, and VRE bacteremia were at greater risk for poor outcome.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10729656     DOI: 10.1016/s0732-8893(99)00136-4

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  41 in total

Review 1.  Effects of antibiotics on nosocomial epidemiology of vancomycin-resistant enterococci.

Authors:  Stephan Harbarth; Sara Cosgrove; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

2.  Association between vancomycin-resistant Enterococci bacteremia and ceftriaxone usage.

Authors:  James A McKinnell; Danielle F Kunz; Eric Chamot; Mukesh Patel; Rhett M Shirley; Stephen A Moser; John W Baddley; Peter G Pappas; Loren G Miller
Journal:  Infect Control Hosp Epidemiol       Date:  2012-05-14       Impact factor: 3.254

3.  Observational study of the epidemiology and outcomes of vancomycin-resistant Enterococcus bacteraemia treated with newer antimicrobial agents.

Authors:  J A McKinnell; M Patel; R M Shirley; D F Kunz; S A Moser; J W Baddley
Journal:  Epidemiol Infect       Date:  2010-11-15       Impact factor: 2.451

4.  Predictors of 12-month outcome in smokers who received bupropion sustained-release for smoking cessation.

Authors:  Gary E Swan; Lisa M Jack; Harold S Javitz; Tim McAfee; Jennifer B McClure
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

5.  Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America.

Authors:  Leonard A Mermel; Michael Allon; Emilio Bouza; Donald E Craven; Patricia Flynn; Naomi P O'Grady; Issam I Raad; Bart J A Rijnders; Robert J Sherertz; David K Warren
Journal:  Clin Infect Dis       Date:  2009-07-01       Impact factor: 9.079

6.  Evaluation of the NanoCHIP® Infection Control Panel test for direct detection and screening of methicillin-resistant Staphylococcus aureus (MRSA), Klebsiella pneumoniae carbapenemase (KPC)-producing bacteria and vancomycin-resistant Enterococcus (VRE).

Authors:  Judith Weiss; Haia Arielly; Nirit Ganor; Yossi Paitan
Journal:  Infection       Date:  2015-03-01       Impact factor: 3.553

7.  Gastrointestinal colonization with a cephalosporinase-producing bacteroides species preserves colonization resistance against vancomycin-resistant enterococcus and Clostridium difficile in cephalosporin-treated mice.

Authors:  Usha Stiefel; Michelle M Nerandzic; Michael J Pultz; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

8.  Outbreak of vancomycin-resistant enterococcus colonization among pediatric oncology patients.

Authors:  Sheila M Nolan; Jeffrey S Gerber; Theoklis Zaoutis; Priya Prasad; Susan Rettig; Kimberly Gross; Karin L McGowan; Anne F Reilly; Susan E Coffin
Journal:  Infect Control Hosp Epidemiol       Date:  2009-04       Impact factor: 3.254

9.  Multicenter study of high-dose daptomycin for treatment of enterococcal infections.

Authors:  Anthony M Casapao; Ravina Kullar; Susan L Davis; Donald P Levine; Jing J Zhao; Brian A Potoski; Debra A Goff; Christopher W Crank; John Segreti; George Sakoulas; Sara E Cosgrove; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2013-06-17       Impact factor: 5.191

10.  Epidemiology and control of an outbreak of vancomycin-resistant enterococci in the intensive care units.

Authors:  Young Kyung Yoon; Hee Sun Sim; Jeong Yeon Kim; Dae Won Park; Jang Wook Sohn; Kyung Ho Roh; Seung Eun Lee; Min Ja Kim
Journal:  Yonsei Med J       Date:  2009-10-21       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.